2 2 London Urology Specialists Limited 11130289 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is specialists medical practice activities. Digita Accounts Production Advanced 6.30.9574.0 true 11130289 2024-01-01 2024-12-31 11130289 2024-12-31 11130289 bus:OrdinaryShareClass1 2024-12-31 11130289 core:CurrentFinancialInstruments 2024-12-31 11130289 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 11130289 core:Non-currentFinancialInstruments 2024-12-31 11130289 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-12-31 11130289 core:CostValuation core:Non-currentFinancialInstruments 2024-12-31 11130289 bus:SmallEntities 2024-01-01 2024-12-31 11130289 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 11130289 bus:AbridgedAccounts 2024-01-01 2024-12-31 11130289 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 11130289 bus:RegisteredOffice 2024-01-01 2024-12-31 11130289 bus:Director1 2024-01-01 2024-12-31 11130289 bus:Director2 2024-01-01 2024-12-31 11130289 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 11130289 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 11130289 bus:Agent1 2024-01-01 2024-12-31 11130289 countries:EnglandWales 2024-01-01 2024-12-31 11130289 core:CostValuation core:Non-currentFinancialInstruments 2023-12-31 11130289 2023-01-01 2023-12-31 11130289 2023-12-31 11130289 bus:OrdinaryShareClass1 2023-12-31 11130289 core:CurrentFinancialInstruments 2023-12-31 11130289 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 11130289 core:Non-currentFinancialInstruments 2023-12-31 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 11130289

London Urology Specialists Limited

Annual Report and Unaudited Abridged Financial Statements

for the Year Ended 31 December 2024

 

London Urology Specialists Limited

Contents

Company Information

1

Directors' Report

2

Abridged Balance Sheet

3 to 4

Notes to the Unaudited Abridged Financial Statements

5 to 6

 

London Urology Specialists Limited

Company Information

Directors

Mr B Khoubehi

Mr R D Smith

Registered office

Anglo House
Worcester Road
Stourport on Severn
DY13 9AW

Accountants

Perrigo Consultants Limited
Certified Chartered AccountantsAnglo House
Worcester Road
Stourport on Severn
DY13 9AW

 

London Urology Specialists Limited

Directors' Report for the Year Ended 31 December 2024

The directors present their report and the abridged financial statements for the year ended 31 December 2024.

Directors of the company

The directors who held office during the year were as follows:

Mr B Khoubehi

Mr R D Smith

Principal activity

The principal activity of the company is specialists medical practice activities.

Small companies provision statement

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the Board on 11 April 2025 and signed on its behalf by:
 

.........................................
Mr B Khoubehi
Director

 

London Urology Specialists Limited

(Registration number: 11130289)
Abridged Balance Sheet as at 31 December 2024

Note

2024
£

2023
£

Fixed assets

 

Investments

4

593,783

548,783

Current assets

 

Debtors

5

100,908

96,295

Cash at bank and in hand

 

133,275

154,265

 

234,183

250,560

Creditors: Amounts falling due within one year

(208,485)

(593,098)

Net current assets/(liabilities)

 

25,698

(342,538)

Total assets less current liabilities

 

619,481

206,245

Accruals and deferred income

 

(28,600)

(26,000)

Net assets

 

590,881

180,245

Capital and reserves

 

Called up share capital

6

450

450

Retained earnings

590,431

179,795

Shareholders' funds

 

590,881

180,245

 

London Urology Specialists Limited

(Registration number: 11130289)
Abridged Balance Sheet as at 31 December 2024

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the Board on 11 April 2025 and signed on its behalf by:
 

.........................................
Mr B Khoubehi
Director

.........................................
Mr R D Smith
Director

 

London Urology Specialists Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 December 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Anglo House
Worcester Road
Stourport on Severn
DY13 9AW

These financial statements were authorised for issue by the Board on 11 April 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

London Urology Specialists Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 December 2024

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2023 - 2).

4

Investments

Total
£

Cost or valuation

At 1 January 2024

548,783

Additions

45,000

At 31 December 2024

593,783

Provision

Carrying amount

At 31 December 2024

593,783

At 31 December 2023

548,783

5

Debtors

Debtors includes £Nil (2023 - £Nil) due after more than one year.

6

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary of £1 each

450

450

450

450